Improvement in Sexual Functioning in Patients With Type 2 Diabetes and Depression Treated With Bupropion

• Published in: Diabetes care Vol. 34; no. 2; pp. 332 - 334
• Main Authors: SAYUK, Gregory S, GOTT, Britt M, NIX, Billy D, LUSTMAN, Patrick J
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.02.2011
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Analysis; Antidepressive Agents, Second-Generation - administration & dosage; Antidepressive Agents, Second-Generation - adverse effects; Biological and medical sciences; Bupropion - administration & dosage; Bupropion - adverse effects; Care and treatment; Depression, Mental; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - epidemiology; Diabetes Mellitus, Type 2 - epidemiology; Diabetes Mellitus, Type 2 - psychology; Diabetes. Impaired glucose tolerance; Diabetics; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Humans; Hyperglycemia; Hyperglycemia - epidemiology; Hyperglycemia - psychology; Independent sample; Male; Medical research; Medical sciences; Medicine, Experimental; Metabolic diseases; Middle Aged; Miscellaneous; Original Research; Prevalence; Public health. Hygiene; Public health. Hygiene-occupational medicine; Risk Factors; Sexual Behavior - drug effects; Sexual disorders; Sexual Dysfunctions, Psychological - drug therapy; Sexual Dysfunctions, Psychological - epidemiology; Studies; Type 2 diabetes; Young Adult; Missouri; Endocrinopathy; Mood disorder; Type 2 diabetes; Human; Nutrition; Depressions; Psychotropic; Depression; Patient; Metabolic diseases; Improvement; Bupropion; Treatment; Endocrinology
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/dc10-1714

Major depressive disorder (MDD) and type 2 diabetes have independent adverse effects on sexual functioning (SF). Bupropion (BU) reportedly has few sexual side effects, but its use in diabetes has not been studied. This article reports a planned secondary analysis of SF in 90 patients with type 2 diabetes treated with BU for MDD. At baseline, 71.1% of patients had insufficient SF. Mean Sexual Energy Scale (SES) scores improved during treatment (P < 0.0001), as did the percentage with sufficient SF (30.6 vs. 68.1%, P = 0.001). Patients with persistent hyperglycemia had higher rates of sexual dysfunction; however, SES improvement was evident in some with persistent depression or hyperglycemia (18.2% and 25.9%, respectively). Insufficient SF is prevalent and may be suspected in patients with MDD and type 2 diabetes. BU treatment of MDD had few sexual side effects and was associated with significant improvements in SF.